Ansofaxine

Ansofaxine

Ansofaxine (pronunciation: an-so-fax-ine) is a triple reuptake inhibitor that is currently under development for the treatment of major depressive disorder and generalized anxiety disorder.

Etymology

The term "Ansofaxine" is derived from the chemical name of the drug, which is "N-[[3-(1-Benzofuran-2-yl)propyl]amino]tetralin". The name "Ansofaxine" is a combination of parts of this chemical name.

Pharmacology

Ansofaxine is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI), also known as a triple reuptake inhibitor (TRI). This means it increases the levels of the neurotransmitters serotonin, norepinephrine, and dopamine in the brain by inhibiting their reuptake into neurons.

Clinical Trials

Ansofaxine has undergone Phase II clinical trials for the treatment of major depressive disorder and generalized anxiety disorder. The results of these trials have shown that Ansofaxine has a good safety profile and is effective in reducing symptoms of depression and anxiety.

Related Terms

• Serotonin-norepinephrine-dopamine reuptake inhibitor
• Major depressive disorder
• Generalized anxiety disorder
• Neurotransmitter
• Clinical trial

See Also

• List of investigational antidepressants
• List of investigational anxiolytics

External links

• Medical encyclopedia article on Ansofaxine
• Wikipedia's article - Ansofaxine

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski